Back to news

CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline

ACCESSWIRE•16/11/2026•07:30 ET
1

Key Highlights

  • ➤CNSP targets first pipeline-building transaction by year-end 2026
  • ➤Cash and equivalents rose to approximately $17.2 million
  • ➤Third-quarter net loss narrowed to approximately $2.5 million
  • ➤Research and development expenses fell to approximately $0.9 million
  • ➤Advanced discussions cover potential neurology, oncology, or rare-disease assets

Expert Statements

Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals

“We are approaching an important inflection point in the evolution of CNS Pharmaceuticals.”

Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals

“Our efforts to identify and evaluate compelling therapeutic opportunities have progressed into advanced discussions with potential counterparties, bringing us closer to establishing the foundation of our next-generation pipeline.”

Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals

“We are encouraged by the quality of the opportunities under consideration and remain intensely focused on translating these discussions into a meaningful transaction.”

Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals

“Our objective is clear: secure a differentiated asset with the potential to drive clinical development, establish a platform for future growth and create long-term shareholder value.”

Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals

“We look forward to delivering on this important strategic priority.”

HOUSTON, TX / ACCESS Newswire / November 16, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2026 and provided an update on its corporate strategy.

CNS Pharmaceuticals continues to make meaningful progress in executing its pipeline expansion strategy, advancing discussions with potential counterparties regarding the acquisition or licensing of innovative therapeutic assets in neurology, oncology or rare disease. The Company remains focused on completing its first pipeline-building transaction by year-end 2026, an important anticipated milestone in its strategic transformation.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in